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Very Important Paper
HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for
the Development of Proteolysis-Targeting Chimeras
(PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)**
Matthias Schiedel,[a] Attila Lehotzky,[c] Sandor Szunyogh,[c] Judit Oláh,[c]
Sören Hammelmann,[b] Nathalie Wössner,[b] Dina Robaa,[d] Oliver Einsle,[e] Wolfgang Sippl,[d]
Judit Ovádi,[c] and Manfred Jung*[b]
We have discovered the sirtuin-rearranging ligands (SirReals) as
a novel class of highly potent and selective inhibitors of the
NAD+-dependent lysine deacetylase sirtuin 2 (Sirt2). In previous
studies, conjugation of a SirReal with a ligand for the E3
ubiquitin ligase cereblon to form a so-called proteolysis-
targeting chimera (PROTAC) enabled small-molecule-induced
degradation of Sirt2. Herein, we report the structure-based
development of a chloroalkylated SirReal that induces the
degradation of Sirt2 mediated by Halo-tagged E3 ubiquitin
ligases. Using this orthogonal approach for Sirt2 degradation,
we show that other E3 ligases than cereblon, such as the E3
ubiquitin ligase parkin, can also be harnessed for small-
molecule-induced Sirt2 degradation, thereby emphasizing the
great potential of parkin to be used as an E3 ligase for new
PROTACs approaches. Thus, our study provides new insights
into targeted protein degradation in general and Sirt2 degrada-
tion in particular.
Introduction
Eighteen specific lysine deacetylases (KDACs) have been
identified in the human genome, and have been grouped into
four classes according to their sequence homology.[1] The seven
mammalian sirtuin isotypes (Sirt1–7), which constitute the class
III KDACs, share an NAD+-dependent catalytic mechanism. The
isotype Sirt2, predominantly localized in the cytoplasm, deace-
tylates a variety of substrates, such as α-tubulin,[2] NFkB,[3]
BubR1,[4] and p53.[5] However, Sirt2 also acts as a nuclear
deacetylase. An important nuclear function of Sirt2 is the global
deacetylation of H4 K16Ac during mitosis.[6] Sirt2-dependent
deacetylation has a major impact on cell-cycle regulation,[2]
autophagy,[7] peripheral myelination,[8] and immune and inflam-
matory response.[9] A dysregulation of Sirt2-mediated deacyla-
tion has been associated with several disease states, including
bacterial infections, type II diabetes, neurodegenerative dis-
eases, and cancer.[10] This highlights Sirt2 as a promising target
for pharmaceutical intervention. The need for suitable tool
compounds to further elucidate the cellular effects of Sirt2-
catalyzed deacylation and validate Sirt2 as a drug target
provoked the discovery of several drug-like Sirt2-selective
small-molecule inhibitors, which have been reviewed
elsewhere.[10]
In 2015, we discovered a new class of highly Sirt2-selective
inhibitors (Figure 1A).[11] These compounds inhibit Sirt2 in the
low-micromolar to nanomolar range, whereas no detectable
inhibition (IC50>100 μM) can be observed for their close
homologues Sirt1 and Sirt3.[11,12] The co-crystal structures of
Sirt2 in complex with 1 or 2 (Figure 1B), which were the first
crystal structures of Sirt2 complexed with Sirt2-selective drug-
like inhibitors,[11a] revealed a unique mode of inhibition that is
characterized by a major rearrangement of the active site of
Sirt2 upon ligand binding. Thus, inhibitors of this class were
referred to as sirtuin rearranging ligands (SirReals) and the
formed induced-fit binding pocket was termed the selectivity
pocket, as it was identified to be the key to Sirt2 selectivity.[11a]
Very soon after we had reported the existence of the selectivity
pocket, it was shown that this pocket accommodates the long-
chain fatty acid of a myristoyl substrate.[13] In the meantime,
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other Sirt2 inhibitors were also shown to gain their isotype
selectivity by targeting the selectivity pocket.[14] Through
conjugation of the propargylated SirReal analogue 3 with
different azido-functionalized building blocks, we generated the
triazole-SirReals 4a and b. These compounds showed increased
Sirt2 affinity, which has been rationalized by X-ray co-crystallog-
raphy to an additional H-bond interaction of the triazole moiety
with Arg97 of the cofactor binding loop (Figure 1B).[12]
Besides an increase in affinity, the incorporation of a triazole
led to improved water solubility and gave the opportunity to
use the triazole as a linker moiety in order to conjugate the
SirReal core with various azido-functionalized labels by means
of CuI-catalyzed Huisgen cycloaddition.[15] Thus, we took advant-
age of the triazole-SirReals as an ideal template for the
straightforward development of small-molecule tools to probe
Sirt2. Fluorescently labelled SirReals were utilized for screening
purposes and as unprecedented tools to study binding to the
selectivity pocket.[16] A biotinylated SirReal was used in combi-
nation with biolayer interferometry for kinetic measurements
that revealed the long residence time of the SirReal-Sirt2
interaction.[12,17] By means of the phthalimide-tagged SirReal
analogue (5), a so-called proteolysis targeting chimera (PRO-
TAC), we were able to induce the proteasomal degradation of
Sirt2.[18] In general, PROTACs are capable of hijacking the cellular
quality control by recruiting the protein of interest (POI) to an
E3 ubiquitin ligases for polyubiquitination and thus to induce
its proteasomal degradation.[19] Currently, ligands for only a few
of over 600 E3 ligases have been harnessed for PROTAC
development.[20] Most commonly employed are phthalimide
analogues leading to recruitment of cereblon, or ligands for the
von Hippel-Lindau protein (VHL) leading to its recruitment.
Besides VHL and cereblon, the E3 ligases cIAP and MDM2
belong to the most frequently used ubiquitin ligases for
PROTAC approaches. Since its first description by Crews and co-
workers in the year 2001, the PROTAC concept has been widely
applied to induce the degradation of various proteins, such as
kinases,[21] transcription factors,[22] and epigenetic reader
proteins.[23] The PROTAC approach has attracted much attention
in the recent years, as it comes along with several benefits
compared to standard small-molecule-based inhibition. From a
basic research point of view, PROTACs can be employed as
tools to prove cellular target engagement.[24] As PROTACs
induce the degradation of the whole protein, they can be used
for the identification of yet unknown protein functions, e.g.
protein-protein-interactions, which are not related to the actual
binding site of the ligand/PROTAC. For example, the Sirt2-
directed PROTAC (5) enabled the discovery of the interplay
between Sirt2 and the tubulin polymerase TPPP/p25 that is not
dependent on the catalytic activity of Sirt2.[25] From a
therapeutic perspective, PROTACs often show an improved
cellular efficacy compared to occupancy-based inhibition, which
is attributed to their catalytic mode of action as well as the
sustained inhibition and disruption of protein-protein interac-
tions as a consequence of target degradation.[26] The first
PROTAC drugs (ARV-110, ARV-471) have recently even entered
phase I clinical trials for treating patients with metastatic
castration resistant prostate cancer and metastatic breast
cancer, respectively,[27] which points out the therapeutic
potential of the PROTAC approach.
However, first cellular mechanisms of resistance for both
cereblon- and VHL-engaging degraders have recently been
discovered. The mechanism of resistance has been attributed to
a loss of the E3 ligase itself or the downregulation of specific
interaction partners of the respective E3 ligase.[28] Therefore,
two major questions arise from this discovery. First, can other
Figure 1. A) Chemical structures of selected SirReals (1–4), and the Sirt2-
targeted PROTAC dSirt2 (5). B) Comparison of the binding mode of SirReal1
(1, PDB ID: 4RMI, orange) and the triazole-based SirReal 4a (PDB ID: 5DY5,
cyan) at human Sirt2 (PDB ID: 5DY5). Hydrogen bonds are shown as dashed
orange lines. The conserved water molecule bridging the interaction of the
SirReals is shown as a red sphere.
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E3 ligases, beyond cereblon, cIAP, MDM2, and VHL, be utilized
for targeted protein degradation? Second, how can new E3
ligases be identified as the potential mediators of chemically
induced protein degradation, in the absence of suitable ligands
enabling their recruitment to the targeted protein?
In order to address these questions, Ottis et al. studied the
suitability of different E3 ligases for small-molecule-induced
protein degradation by fusing different E3 ligases to HaloTag 7
(HT7).[29] Thereby, they replaced the native substrate binding
domain of the respective E3 ligase with HT7, which is an
engineered bacterial dehalogenase capable of forming a
covalent bond with a chloroalkane under in vitro and in vivo
conditions.[30] This system was used to present chloroalkylated
ligands for the protein of interest (POI) on the surface of E3
ligase-HT7 fusion proteins, thereby enabling the recruitment of
the POI to the HT7-tagged E3 ligase. Due to this chemically
induced interaction, the ubiquitination and subsequent protea-
somal degradation of the POI can be initiated, if the HT7-tagged
E3 ligase is suitable for chemically induced target degradation.
By this elegant approach the authors bypassed the need for
previously identified ligands for the native substrate binding
site of the respective E3 ligase. In the course of their study, Ottis
et al. identified the E3 ligase parkin to have the broadest
efficacy for the degradation of endogenous target proteins
(ABL1, SRC, YES, and EphA2). Moreover, the HT7-parkin
construct showed the broadest capability to accommodate
diverse linker lengths and linker compositions.[29] In order to
investigate the potential of parkin as an E3 ligase that can be
broadly utilized for targeted protein degradation and to provide
an unprecedented molecular tool to probe Sirt2 biology, we
have developed a chloroalkylated SirReal and studied its
efficacy for degrading Sirt2 in presence of different HT7-tagged
E3 ligases. In addition, molecular modeling of the ternary
complex of Sirt2, HT7, and the SirReal-probe proposes a binding
model of the interaction of the bifunctional ligand with both
binding pockets.
Results
For the design of the chloroalkylated SirReal, we combined the
structural features of the Sirt2-selective and highly potent
triazole-based SirReals (see Figure 1) with 2-((6-chlorohexyl)oxy)
ethyl, a reactive linker that has been previously developed for
the HaloTag labeling technology.[30a] Based on our work on a
SirReal-based affinity probe,[12,31] we already had valid informa-
tion on where to place the linker without losing affinity to Sirt2.
In addition, docking studies and molecular dynamics simula-
tions of Sirt2-HT7-probe ternary complexes were carried out, in
order to design suitable linkers between the triazole-SirReal and
the chloroalkyl group. To model the ternary complex of Sirt2-
HT7-triazole-SirReal probe, the crystal structures of human Sirt2
complexed with a triazole-SirReal 4a[12] and the HT7 crystal
structure from Rhodococcus rhodochrous[32] with a covalently
bound chloroalkane-based ligand were used. The protein-
protein docking was carried out using program HADDOCK[33] as
described in detail in the experimental section (Supporting
Information, Figure S1). We predicted a 2-(2-((6-chlorohexyl)oxy)
ethoxy)ethyl linker to be suitable to recruit Sirt2 to HT7 with an
adequate proximity that allows the formation of the covalent
bond between the probe and Asp105. The obtained binary
Sirt2-HT7 complex was subsequently used to dock the designed
probe assuming the formation of a covalent bond between the
terminal chloroalkane and Asp105. The docking results show
that the triazole-SirReal and the 2-(2-((hexyl)oxy)ethoxy)ethyl
group are interacting in a similar way as the co-crystallized
molecules in Sirt2 (PDB ID: 5DY5) and HT7 (PDB ID: 5VNP;
Figures 2, S2, and S3).
To analyze the stability of the obtained ternary Sirt2-HT7-
probe complex, we carried out a 50 ns molecular dynamics
(MD) simulation (see Supporting Information for details). The
complex as well as the individual proteins remained stable
during the simulation time with Cα-atom RMSD values around
2 Å (Figure S4). Also the ligand changed its binding conforma-
tion only slightly (RMSD values of heavy atoms between 2 and
3 Å), esp. the SirReal part of the probe showed the same
interaction with the Sirt2 protein as the unmodified SirReal
inhibitor in the crystal structure. Only the flexible linker region
including the triazole group, located at the interface of both
proteins, showed higher flexibility during the MD simulation
(the superimposition of six different complex conformations at
0, 10, 20, 30, 40, 50 ns is shown in Figure S5.
In order to synthesize the envisaged chloroalkylated SirReal
(11), we set up the synthesis route depicted in Scheme 1. While
planning this synthesis route, we focused our efforts on i)
generating the chloroalkylated SirReal 11, capable of inducing
Sirt2 degradation ii) providing a “click-able” azido-chloroalkyl-
conjugate as a versatile HaloTag substrate ready for conjugation
with other alkynylated ligands.
In the first step of our synthesis route, 1-chloro-6-iodohex-
ane (6) was used for the alkylation of the primary alcohol (7) to
form the ether (8). The amine (9) was generated by removing
the tert-butyloxycarbonyl protecting group by the addition of
trifluoroacetic acid. A diazotransfer reaction was used to form
Figure 2. Model of the ternary complex of Sirt2-HT7 with covalently bound
chloroalkylated SirReal probe 11 (ball and stick mode, colored green). Sirt2 is
shown as orange coloured ribbon and HT7 as cyan coloured ribbon. Probe
surrounding amino acids are displayed as well as the molecular surface of
the resulting binding pocket (color-coded according to the hydrophobicity,
hydrophobic region: green, polar region: magenta).
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the “click-able” azido-chloroalkyl-conjugate (10). Finally, com-
pound 10 was conjugated with the propargylated SirReal
analogue 3 through a CuI-catalyzed Huisgen cycloaddition[15] to
yield the chloroalkylated SirReal (11).
The chloroalkylated SirReal (11) was evaluated for its in vitro
inhibition of Sirt2 in a fluorescence-based deacetylase activity
assay as previously described.[34] As expected, a potent inhib-
ition of Sirt2 with an IC50 value of 0.74�0.02 μM was observed,
whereas Sirt1 and Sirt3, the closest homologues of Sirt2, were
only affected at much higher concentrations (Scheme 1).
To assess the suitability of the chloroalkylated SirReal (11)
for chemically induced Sirt2 degradation, we transfected HeLa
cells with plasmids coding for a small panel of engineered HT7-
tagged E3 ligases, covering the three major classes of E3 ligases:
U-box, HECT, and RING. The plasmids for the engineered HT7-
tagged E3 ligases HT7-NEDD4L, MARCH5-HT7, SIAH1-HT7, HT7-
parkin, βTrCP-HT7, and HT7-CHIP have been previously devel-
oped by Ottis et al. and were a generous gift from the Crews
laboratory.[29] By immunofluorescence microscopy and Western
blot experiments, we were able to show the expression of the
HT7-E3 constructs in human HeLa cells; however, the extent of
the expression seemed to be highly dependent on the nature
of the constructs as well as the approach used for the detection
(Figures 3 and S6). The immunofluorescence microscopic visual-
ization has shown unambiguous immunopositivity of the
engineered HT7-parkin, βTrCP-HT7, and HT7-CHIP plasmids,
comparable staining with the control (empty plasmid) (Fig-
ure 3). The Western blot analyses provided additional evidence
for the significant expression of these three constructs,
although their immunopositivities appear to be dependent on
the antibodies specific for the HaloTag or HA-tag of the
constructs (Figure S6).
To investigate whether the three well-expressed HaloTag E3
ligase constructs (HT7-parkin, βTrCP-HT7, and HT7-CHIP) can
mediate Sirt2 degradation induced by 11, the intracellular level
of the tubulin deacetylase was quantified in HeLa cells by
Western blot using a Sirt2-specific antibody. As shown in
Figure 4A, the engineered constructs HT7-parkin, βTrCP-HT7,
and HT7-CHIP display an effect on the Sirt2 level, as compared
to the control experiments (empty vector). The quantification of
the concentration-dependent effect of the fusion constructs
reveals that the most effective construct is HT7-parkin (Fig-
ure 4B). It already induces marked Sirt2 degradation at a
concentration of 20 nM of the chloroalkylated SirReal (11),
whereas tenfold higher concentrations of our previously
reported cereblon-mediated PROTAC (5) were required to
provoke similar effects.[18] Moreover, we were able to show that
the effect of 11 on Sirt2 degradation can be counteracted either
by the proteasome inhibitor MG132[35] or by competition with
the Sirt2 inhibitor 4b[12] and the HaloTag competitor HT7-L,
respectively (Figure 4C). Even though MG132 could only reduce
but not fully counteract the Sirt2 degradation, these findings
indicate that observed reduction of Sirt2 levels can be
attributed to chemically induced protein degradation by our
chloroalkylated SirReal (11). To investigate the functional
consequences of Sirt2 degradation by means of 11, we probed
the acetylation levels of tubulin, a well-known Sirt2 substrate,[2]
via immunofluorescence microscopy using a specific anti-
acetylated-tubulin antibody (Figure 4D). In cells expressing HT7-
Scheme 1. Synthesis of the chloroalkylated SirReal (11). a) NaH, THF/CH2Cl2
(2 : 1), 0 °C–RT, 12 h, 33% yield; b) TFA, CH2Cl2, 0 °C–RT, 2 h,�99% yield
(crude); c) 1H-imidazole-1-sulfonyl azide hydrochloride, CuSO4, K2CO3,
methanol, RT, 2 h, 47% yield; d) 3, sodium ascorbate, CuSO4, water/tert-
BuOH (1 :1), RT, 16 h, yield 79% yield. IC50 values are indicated as mean
value� standard deviation (n=3).
Figure 3. The expression of HaloTag E3 ligase constructs in transiently
transfected HeLa cells. 0: empty plasmid (no E3), 1: HT7-NEDD4L, 2: MARCH-
HT7, 3: SIAH-HT7, 4: HT7-parkin, 5: βTrCP-HT7, and 6: HT7-Chip, respectively.
Transfected cells are stained by specific fluorescent HaloTag TMR Ligand
(HT7-L, 50 nM) and detected as red signal by immunofluorescence micro-
scopy. Scale bar: 10 μm.
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parkin (red), degradation of Sirt2 due to treatment with 11
resulted in a more pronounced acetylation of the microtubule
network as compared to cells where 11 can only act as a Sirt2
inhibitor due to the absence of HT7-parkin. The observation
that treatment with our chloroalkylated SirReal (11) in combina-
tion with HT7-parkin expression results in a more pronounced
hyperacetylation of the tubulin network, as compared to our
cereblon-mediated PROTAC (5), is consistent with the high
activity of 11 detected by means of our western blot experi-
ments (Figure 4A  B). However, when comparing the effects of
11 and 5, it should be taken into account that the effects of 11
are mediated by an artificially expressed fusion protein (HT7-
parkin), whereas Sirt2 degradation induced by the thalidomide-
labelled PROTAC (5) is mediated by endogenous expression of
the E3 ligase cereblon.
Discussion and Conclusion
In this study, we report the structure-based development of a
chloroalkylated sirtuin rearranging ligand (SirReal) that induces
the degradation of Sirt2 mediated by Halo-tagged E3 ligases.
While the approach of targeted protein degradation mediated
by Halo-tagged E3 ligases has been established for kinases and
binding proteins,[29] this is the first example of a chloroalkylated
PROTAC targeting an amidohydrolase or any histone modifying
enzyme. On the one hand, our study shows the versatility of
this approach developed by Ottis et al.,[29] on the other hand,
we were able to expand our SirReal-based chemical biology
toolset, thereby highlighting the SirReals as an ideal template
for the development of further Sirt2-targeted molecular tools.
Moreover, with our azido-chloroalkyl-conjugate (10) we provide
a versatile HaloTag ligand building block, ready to be “clicked”
to alkynylated ligands targeting other proteins. Given the broad
functional group tolerance of this type of chemistry[36] and the
availability of alkynylated ligands for many targets that have
been used in a large variety of chemical biology studies, this
technique will be amenable to a plethora of different targets
and inhibitors. Most importantly, by means of our chloroalky-
lated SirReal (11) we were able to validate the broad substrate
spectrum of HT7-parkin, thereby emphasizing the great
potential of parkin to be utilized as an E3 ligase for new
approaches in targeted protein degradation. This finding is
highly relevant as mechanisms of drug resistance have been
recently reported for PROTAC approaches mediated by the
most frequently used E3 ligases cereblon and VHL.[28]
Figure 4. The chloroalkylated SirReal (11) induces the proteasomal degradation of Sirt2 in HeLa cells transiently co-transfected with EGFP-Sirt2 and different
Halo-tagged E3 ligase constructs. A) Representative Western blots showing the effect of E3-HaloTag constructs on the intracellular EGFP-Sirt2 level in the
presence of 11 (0.02 μM – 2 μM, exposure time=4 h). B) Western blot was detected by using a Sirt2 specific antibody and quantified by densitometry. The
values are normalized with respect to 0 μM of 11 for each plasmid. The obtained values are indicated as mean value � standard deviation (n=3). Curves for
HT7-CHIP and HT7-parkin were fitted using OriginPro 2018 software by non-linear curve fitting applying a one-phase decay model. C) Representative Western
blot image detected by Sirt2-specific antibody shows the effect of 11 on the EGFP-Sirt2 level in the absence and presence of the proteasome inhibitor MG132,
the HaloTag blocker HT7-L, and the Sirt2 inhibitor 4b (n=4). D) Immunofluorescence microscopic images of HeLa cells stained for acetyl-tubulin
immunopositivity (green). In cultured HeLa cells expressing HT7-parkin (red, labelled with 50 nM fluorescent HaloTag TMR Ligand (HT7-L)), depletion of Sirt2
due to treatment with 11 results in a more pronounced acetylation of the microtubule network (green), as compared to cereblon-mediated Sirt2 degradation
by 5 or sole enzymatic inhibition by 11 in the absence of HT7-parkin. Samples were pre-incubated with compounds at 1 μM concentration. Nuclei were DAPI
stained (blue). Scale bar: 10 μm.
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It’s degrading: We report the
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ligand (SirReal) that induces Sirt2
degradation mediated by Halo-
tagged E3 ubiquitin ligases. Using
this approach, we show that besides
cereblon, other E3 ligases such as
parkin, can be harnessed for small-
molecule-induced Sirt2 degradation.
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